开云app官网登录入口网页版-官方正版

#三期临床试验#

29篇内容 | 1285人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2030048, encodeId=2e882030048ba, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, objectTitle=国产新冠口服药VV116对比PAXLOVID三期临床试验获得成功, objectType=article, longId=727732, objectId=4596e27732ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4596e27732ba, replyNumber=0, likeNumber=98, createdTime=2023-01-24, rootId=0, userName=12498bf3m25暂无昵称, userId=0d342500153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4596e27732ba, moduleTitle=国产新冠口服药VV116对比PAXLOVID三期临床试验获得成功, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4596e27732ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2030046, encodeId=bd1c203004607, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, objectTitle=欧康维视生物OT-502获批三期临床试验，纳入博鳌乐城先行区真实世界数据应用试点品种, objectType=article, longId=217197, objectId=d53a21e197bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d53a21e197bf, replyNumber=0, likeNumber=82, createdTime=2021-09-20, rootId=0, userName=12498bf3m25暂无昵称, userId=0d342500153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d53a21e197bf, moduleTitle=欧康维视生物OT-502获批三期临床试验，纳入博鳌乐城先行区真实世界数据应用试点品种, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d53a21e197bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2030044, encodeId=b24f2030044fe, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, objectTitle=科兴灭活疫苗巴西三期临床试验结果出炉！, objectType=article, longId=209930, objectId=412420993098, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=412420993098, replyNumber=0, likeNumber=83, createdTime=2021-10-26, rootId=0, userName=12498bf3m25暂无昵称, userId=0d342500153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=412420993098, moduleTitle=科兴灭活疫苗巴西三期临床试验结果出炉！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=412420993098)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2030047, encodeId=f870203004e46, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, objectTitle=普克鲁胺治疗轻中度新冠三期临床试验的期中分析未获阳性结果，给我们有哪些启示？, objectType=article, longId=292989, objectId=e862292989a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e862292989a0, replyNumber=0, likeNumber=74, createdTime=2022-07-15, rootId=0, userName=12498bf3m25暂无昵称, userId=0d342500153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e862292989a0, moduleTitle=普克鲁胺治疗轻中度新冠三期临床试验的期中分析未获阳性结果，给我们有哪些启示？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e862292989a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2030045, encodeId=42e02030045fc, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, objectTitle=德国CureVac新冠疫苗三期临床试验有效性仅为47%，病毒变异疫苗开发挑战增加, objectType=article, longId=212858, objectId=6bb6212858c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6bb6212858c0, replyNumber=0, likeNumber=81, createdTime=2022-03-03, rootId=0, userName=12498bf3m25暂无昵称, userId=0d342500153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6bb6212858c0, moduleTitle=德国CureVac新冠疫苗三期临床试验有效性仅为47%，病毒变异疫苗开发挑战增加, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6bb6212858c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2030043, encodeId=e48d203004323, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, objectTitle=礼来的双抗体鸡尾酒疗法三期临床试验获得重要进展, objectType=article, longId=208253, objectId=ad502082536a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad502082536a, replyNumber=0, likeNumber=53, createdTime=2022-02-19, rootId=0, userName=12498bf3m25暂无昵称, userId=0d342500153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad502082536a, moduleTitle=礼来的双抗体鸡尾酒疗法三期临床试验获得重要进展, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ad502082536a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2030042, encodeId=bdae20300427a, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, objectTitle=又一大利好消息！Moderna新冠疫苗三期临床试验有效性高达94.5%, objectType=article, longId=203490, objectId=f3d72034907f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3d72034907f, replyNumber=0, likeNumber=89, createdTime=2021-06-06, rootId=0, userName=12498bf3m25暂无昵称, userId=0d342500153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3d72034907f, moduleTitle=又一大利好消息！Moderna新冠疫苗三期临床试验有效性高达94.5%, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f3d72034907f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2030035, encodeId=75572030035a1, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, objectTitle=J Immunother Cancer：抗PD1单药治疗头颈部鳞状细胞癌患者三期临床试验的比较分析, objectType=article, longId=196280, objectId=fe3c1962807f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe3c1962807f, replyNumber=0, likeNumber=105, createdTime=2021-03-19, rootId=0, userName=12498bf3m25暂无昵称, userId=0d342500153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe3c1962807f, moduleTitle=J Immunother Cancer：抗PD1单药治疗头颈部鳞状细胞癌患者三期临床试验的比较分析, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fe3c1962807f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2030036, encodeId=245920300366e, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, objectTitle=8月8日全球新冠肺炎（COVID-19）疫情简报，确诊超1952万，6种疫苗进入三期临床试验，中国占3个, objectType=article, longId=199004, objectId=6cee19900470, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cee19900470, replyNumber=0, likeNumber=112, createdTime=2021-03-05, rootId=0, userName=12498bf3m25暂无昵称, userId=0d342500153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cee19900470, moduleTitle=8月8日全球新冠肺炎（COVID-19）疫情简报，确诊超1952万，6种疫苗进入三期临床试验，中国占3个, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6cee19900470)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2030041, encodeId=84662030041f1, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, objectTitle=Lancet oncol：因疗效太好，国产药索凡替尼用于晚期胰腺神经内分泌瘤的三期临床试验提前终止！, objectType=article, longId=201127, objectId=84cb20112e76, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84cb20112e76, replyNumber=0, likeNumber=80, createdTime=2021-04-04, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84cb20112e76, moduleTitle=Lancet oncol：因疗效太好，国产药索凡替尼用于晚期胰腺神经内分泌瘤的三期临床试验提前终止！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=84cb20112e76)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2030039, encodeId=6ff1203003995, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, objectTitle=因志愿者出现疑似严重不良反应，阿斯利康暂停新冠疫苗三期临床试验, objectType=article, longId=200492, objectId=53c7200492b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53c7200492b6, replyNumber=0, likeNumber=85, createdTime=2021-06-05, rootId=0, userName=12498bf3m25暂无昵称, userId=0d342500153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53c7200492b6, moduleTitle=因志愿者出现疑似严重不良反应，阿斯利康暂停新冠疫苗三期临床试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=53c7200492b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2030037, encodeId=d84f203003ebd, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, objectTitle=陈薇团队新冠疫苗海外开展三期临床试验, objectType=article, longId=200414, objectId=ced6200414c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ced6200414c8, replyNumber=0, likeNumber=82, createdTime=2021-02-09, rootId=0, userName=12498bf3m25暂无昵称, userId=0d342500153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ced6200414c8, moduleTitle=陈薇团队新冠疫苗海外开展三期临床试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ced6200414c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2030038, encodeId=d851203003872, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, objectTitle=阿斯利康/牛津大学新冠疫苗三期临床试验因疑似不良反应触发中止机制, objectType=article, longId=200464, objectId=cb582004641e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb582004641e, replyNumber=0, likeNumber=89, createdTime=2021-08-21, rootId=0, userName=12498bf3m25暂无昵称, userId=0d342500153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb582004641e, moduleTitle=阿斯利康/牛津大学新冠疫苗三期临床试验因疑似不良反应触发中止机制, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=cb582004641e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2030040, encodeId=6891203004045, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, objectTitle=辉瑞与BioNTech：三期临床试验规模扩大，最终结果10月底见分晓, objectType=article, longId=200679, objectId=181a2006e961, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=181a2006e961, replyNumber=0, likeNumber=0, createdTime=2021-05-02, rootId=0, userName=12498bf3m25暂无昵称, userId=0d342500153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=181a2006e961, moduleTitle=辉瑞与BioNTech：三期临床试验规模扩大，最终结果10月底见分晓, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=181a2006e961)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2030034, encodeId=988c20300347c, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, objectTitle=科兴生物新冠病毒疫苗初步显示安全有效！三期临床试验将在中国和巴西进行, objectType=article, longId=196013, objectId=c3f3196013e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3f3196013e0, replyNumber=0, likeNumber=78, createdTime=2021-02-05, rootId=0, userName=12498bf3m25暂无昵称, userId=0d342500153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3f3196013e0, moduleTitle=科兴生物新冠病毒疫苗初步显示安全有效！三期临床试验将在中国和巴西进行, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c3f3196013e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2030033, encodeId=b6be203003317, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, objectTitle=联康集团**全生物表达新药三期临床试验申请获国家药监局受理, objectType=article, longId=154427, objectId=dd5415442ec3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd5415442ec3, replyNumber=0, likeNumber=91, createdTime=2019-08-21, rootId=0, userName=12498bf3m25暂无昵称, userId=0d342500153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd5415442ec3, moduleTitle=联康集团**全生物表达新药三期临床试验申请获国家药监局受理, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=dd5415442ec3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2030032, encodeId=3763203003246, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, objectTitle=阿斯利康狼疮药物anifrolumab未能到达三期临床试验的主要终点, objectType=article, longId=148032, objectId=3e5614803226, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e5614803226, replyNumber=0, likeNumber=0, createdTime=2019-03-10, rootId=0, userName=12498bf3m25暂无昵称, userId=0d342500153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e5614803226, moduleTitle=阿斯利康狼疮药物anifrolumab未能到达三期临床试验的主要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3e5614803226)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2030031, encodeId=90f02030031a5, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, objectTitle=J Clin Oncol：新药彭溴利唑，治疗中晚期癌症，三期临床试验成功, objectType=article, longId=125970, objectId=0df11259e00f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0df11259e00f, replyNumber=0, likeNumber=86, createdTime=2018-03-09, rootId=0, userName=12498bf3m25暂无昵称, userId=0d342500153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0df11259e00f, moduleTitle=J Clin Oncol：新药彭溴利唑，治疗中晚期癌症，三期临床试验成功, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0df11259e00f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2030030, encodeId=e1ad2030030df, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, objectTitle=重磅：国家重大新药项目“皮卡狂犬病疫苗”开启国际多中心三期临床试验, objectType=article, longId=115958, objectId=be6111595856, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be6111595856, replyNumber=0, likeNumber=83, createdTime=2017-11-08, rootId=0, userName=12498bf3m25暂无昵称, userId=0d342500153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be6111595856, moduleTitle=重磅：国家重大新药项目“皮卡狂犬病疫苗”开启国际多中心三期临床试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=be6111595856)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2030029, encodeId=c78f203002941, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, objectTitle=Keytruda治疗头颈癌三期临床试验未达主要终点(Keynote-040研究), objectType=article, longId=106852, objectId=5c6a10685217, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c6a10685217, replyNumber=0, likeNumber=85, createdTime=2017-08-07, rootId=0, userName=12498bf3m25暂无昵称, userId=0d342500153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c6a10685217, moduleTitle=Keytruda治疗头颈癌三期临床试验未达主要终点(Keynote-040研究), moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5c6a10685217)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

三期临床试验

2020-05-29

12498bf3m25暂无昵称 (审核中...)

前往app查看评论内容

#三期临床试验#

国产新冠口服药VV116对比PAXLOVID三期临床试验获得成功

2023-01-24

12498bf3m25暂无昵称 (审核中...)

前往app查看评论内容

#三期临床试验#

欧康维视生物OT-502获批三期临床试验，纳入博鳌乐城先行区真实世界数据应用试点品种

2021-09-20

12498bf3m25暂无昵称 (审核中...)

前往app查看评论内容

#三期临床试验#

科兴灭活疫苗巴西三期临床试验结果出炉！

2021-10-26

12498bf3m25暂无昵称 (审核中...)

前往app查看评论内容

#三期临床试验#

普克鲁胺治疗轻中度新冠三期临床试验的期中分析未获阳性结果，给我们有哪些启示？

2022-07-15

12498bf3m25暂无昵称 (审核中...)

前往app查看评论内容

#三期临床试验#

德国CureVac新冠疫苗三期临床试验有效性仅为47%，病毒变异疫苗开发挑战增加

2022-03-03

12498bf3m25暂无昵称 (审核中...)

前往app查看评论内容

#三期临床试验#

礼来的双抗体鸡尾酒疗法三期临床试验获得重要进展

2022-02-19

12498bf3m25暂无昵称 (审核中...)

前往app查看评论内容

#三期临床试验#

又一大利好消息！Moderna新冠疫苗三期临床试验有效性高达94.5%

2021-06-06

12498bf3m25暂无昵称 (审核中...)

前往app查看评论内容

#三期临床试验#

J Immunother Cancer：抗PD1单药治疗头颈部鳞状细胞癌患者三期临床试验的比较分析

2021-03-19

12498bf3m25暂无昵称 (审核中...)

前往app查看评论内容

#三期临床试验#

8月8日全球新冠肺炎（COVID-19）疫情简报，确诊超1952万，6种疫苗进入三期临床试验，中国占3个

2021-03-05

heli0118 (审核中...)

前往app查看评论内容

#三期临床试验#

Lancet oncol：因疗效太好，国产药索凡替尼用于晚期胰腺神经内分泌瘤的三期临床试验提前终止！

2021-04-04

12498bf3m25暂无昵称 (审核中...)

前往app查看评论内容

#三期临床试验#

因志愿者出现疑似严重不良反应，阿斯利康暂停新冠疫苗三期临床试验

2021-06-05

12498bf3m25暂无昵称 (审核中...)

前往app查看评论内容

#三期临床试验#

陈薇团队新冠疫苗海外开展三期临床试验

2021-02-09

12498bf3m25暂无昵称 (审核中...)

前往app查看评论内容

#三期临床试验#

阿斯利康/牛津大学新冠疫苗三期临床试验因疑似不良反应触发中止机制

2021-08-21

12498bf3m25暂无昵称 (审核中...)

前往app查看评论内容

#三期临床试验#

辉瑞与BioNTech：三期临床试验规模扩大，最终结果10月底见分晓

2021-05-02

12498bf3m25暂无昵称 (审核中...)

前往app查看评论内容

#三期临床试验#

科兴生物新冠病毒疫苗初步显示安全有效！三期临床试验将在中国和巴西进行

2021-02-05

12498bf3m25暂无昵称 (审核中...)

前往app查看评论内容

#三期临床试验#

联康集团**全生物表达新药三期临床试验申请获国家药监局受理

2019-08-21

12498bf3m25暂无昵称 (审核中...)

前往app查看评论内容

#三期临床试验#

阿斯利康狼疮药物anifrolumab未能到达三期临床试验的主要终点

2019-03-10

12498bf3m25暂无昵称 (审核中...)

前往app查看评论内容

#三期临床试验#

J Clin Oncol：新药彭溴利唑，治疗中晚期癌症，三期临床试验成功

2018-03-09

12498bf3m25暂无昵称 (审核中...)

前往app查看评论内容

#三期临床试验#

重磅：国家重大新药项目“皮卡狂犬病疫苗”开启国际多中心三期临床试验

2017-11-08

12498bf3m25暂无昵称 (审核中...)

前往app查看评论内容

#三期临床试验#

Keytruda治疗头颈癌三期临床试验未达主要终点(Keynote-040研究)

2017-08-07

科室
- - 订阅+
  - 更多科室
工具
服务